Bryan Dunn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Beyond their control like the economy and the fiscal cliff . I think overall it was more probably 70 to 80 factors beyond the retailers control. I think retailers had creative merchandise but i think the news didnt lead to a feel good factor. In any economy, good or bad, you always have some winners. Who did really well this year . Well, it looks like in terms of who did well so far, Companies Like American Eagle outfitters limited, michael cors, macys tj and i would say costco was also a winner. On the flip side were there retailers that you had high hopes for going into the season but just d...

This is n. B. R. Susie good evening everyone. Im susie gharib. Tom hudson will be along a little later in the program. Hohum sales for the nations retailers this christmas, ringing up the worst Holiday Season in four years, we talk with a top retail analyst. President obama and congressional leaders cut their vacations short, to deal with fiscal cliff negotiations. They have five days to make a deal. And housing continues to be the bright spot in the u. S. Economy home prices post their biggest advance in two years. That and more tonight on n. B. R. christmas may be over, but the Holiday Shopp...

Beyond their control like the economy and the fiscal cliff . I think overall it was more probably 70 to 80 factors beyond the retailers control. I think retailers had creative merchandise but i think the news didnt lead to a feel good factor. In any economy, good or bad, you always have some winners. Who did really well this year . Well, it looks like in terms of who did well so far, Companies Like American Eagle outfitters limited, michael cors, macys tj and i would say costco was also a winner. On the flip side were there retailers that you had high hopes for going into the season but just d...

BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today

-Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus